This site is part of the Global Exhibitions Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Next Pharmaceuticals Acquires Sytrinol

SALINAS, Calif.—Next Pharmaceuticals acquired the distribution rights, patents, trademarks and scientific knowledge for Sytrinol from KGK Synergize.

Currently, Proprietary Nutritionals Inc. sells Sytrinol, and the company will maintain distribution rights until December 31, 2013. Sytrinol is a patented and proprietary formula derived from natural citrus and palm fruit extracts. The formula combines polymethoxylated flavones (PMFs) and delta, gamma and alpha tocotrienols.

Clinical research shows Sytrinol aids in improving total cholesterol, low-density lipoprotein (LDL) cholesterol and triglyceride levels up to 30 percent, 27 percent and 34 percent respectively, compared to placebo levels. Sytrinol has also been shown to increase high-density lipoprotein (HDL) cholesterol, and it works as a powerful antioxidant. Sytrinol has been granted self-affirmed GRAS (generally recognized as safe) status.

Other proprietary formulations from Next include Relora for stress management and Seditol for improved sleep, which recently earned KOF-K certification.

comments powered by Disqus